What’s driving Singapore’s advanced manufacturing boom?

Additive manufacturing is also seeing growth.

Artificial intelligence and advanced innovation are accelerating the growth of Singapore’s advanced manufacturing sector, according to the SGInnovate Singapore Early-Stage Emerging Tech Startups 2024 Landscape Report.

The report said that the additive manufacturing is seeing growth from the increasing use of 3D-printed components in aerospace, supported by the new SS 708 standard, and in healthcare, with AI integration expected to transform design and production processes.

Demand for advanced materials is rising across sectors such as electric vehicles, aerospace, defence, and healthcare, though investors face capital and regulatory hurdles.

Technologies with capabilities such as self-healing, temperature regulation, CO₂ capture, and alternative mineral sourcing are seen as particularly transformative.

The automation sector is shifting from hardware-centric models toward AI-powered, software-driven platforms that enable robot orchestration across systems.

The rise of no-code programming tools and embodied AI is also making robotics more adaptive and intuitive. Singapore’s strong base in electronics manufacturing, coupled with its ambitions to become a hub for AI and semiconductor innovation, is driving growth in sensors and electronics. Budget 2025’s announcement of a $500m national fabrication facility underscores this momentum.

Meanwhile, Singapore’s nascent space technology sector is gaining support through initiatives such as the Space Accelerator Programme and an additional $60m government investment, focusing on satellite communications and solutions for maritime, finance, and climate challenges.

The agrifood sector is shifting towards biological innovation to enhance upstream production and enable cost-efficient scaling.

Whilst traditional infrastructure investments remain relevant, new developments in biocontrols, biostimulants, genetic editing, and disease prevention are reshaping sustainable agriculture, including aquaculture.

Alternative proteins continue to face sales challenges due to price sensitivity and regulatory uncertainty, but consumer interest in minimally processed, clean-label products signals future potential.

The launch of the Bezos Centre for Sustainable Protein at NUS in 2024 highlights Singapore’s role in driving innovation in this space.

Food supply chain technologies are becoming increasingly critical as geopolitical risks heighten concerns over stability. Blockchain, big data solutions, and advanced pathogen detection are key to ensuring safety and resilience.

At the same time, the functional foods market is expanding as consumers seek personalised nutrition and targeted health benefits, though cost-intensive extraction and formulation processes present opportunities for innovation.

Sustainability-focused startups are gaining momentum by applying advances in materials and data science to energy and resource challenges, but scaling solutions within existing infrastructure remains essential.

Decarbonisation efforts are moving beyond emission reduction to include carbon capture, utilisation, and storage technologies, alongside carbon accounting and green credit systems that incentivise reductions.

Singapore is also exploring nuclear fission and fusion as part of its renewable energy strategy. Interest in energy optimisation is rising, with startups developing battery diagnostics and novel chemistries that boost energy density and efficiency.

Investment in sustainable materials is also increasing, with companies working on biopolymer alternatives to petrochemicals and AI-driven materials discovery.

Waste management is shifting toward circular economy models, with solutions that convert waste into resources like syngas, although the high capital intensity of these technologies continues to limit adoption.

In health and biomedical sciences, AI and personalised medicine are driving new waves of innovation and investment.

Medical devices are seeing renewed investor attention, particularly in AI-driven tools, cardiovascular technologies, minimally invasive devices, and digital health products.

Diagnostics are advancing through multi-omics, point-of-care solutions, and AI-powered platforms that enable personalised treatment pathways. Oncology remains a key focus for therapeutics, alongside gene and cell therapies.

Rare diseases are also attracting investment due to regulatory incentives and high unmet needs. AI in drug discovery is gaining traction, but models require stronger data foundations, often accessible only through partnerships with large pharmaceutical companies.

Singapore is positioning itself at the forefront of these efforts with the launch of the Ignition AI Accelerator in partnership with Pfizer in 2024 and through collaborations between the Experimental Drug Development Centre and AI-driven startups.